Back to top
more

Genmab (GMAB)

(Delayed Data from NSDQ)

$28.24 USD

28.24
550,025

-0.11 (-0.39%)

Updated Aug 2, 2024 04:00 PM ET

After-Market: $28.24 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Wall Street Analysts Think Genmab (GMAB) Could Surge 45.08%: Read This Before Placing a Bet

by Zacks Equity Research

The consensus price target hints at a 45.1% upside potential for Genmab (GMAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Nalak Das headshot

Buy 2 Biotech Bigwigs Set to Gain on Possible Earnings Beat

by Nalak Das

Two biotech bigwigs set to beat on earnings next week are: ILMN, GMAB.

Kinjel Shah headshot

Should You Buy AbbVie (ABBV) After Q2 Beat, Guidance Raise?

by Kinjel Shah

Investors who own AbbVie's (ABBV) stock may stay invested as the company has faced its biggest challenge, Humira's patent cliff, quite well and looks set to return to robust growth next year.

All You Need to Know About Genmab (GMAB) Rating Upgrade to Strong Buy

by Zacks Equity Research

Genmab (GMAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

GMAB vs. CSLLY: Which Stock Is the Better Value Option?

by Zacks Equity Research

GMAB vs. CSLLY: Which Stock Is the Better Value Option?

AbbVie (ABBV) Beats on Q2 Earnings & Sales, Ups '24 EPS View

by Zacks Equity Research

AbbVie's (ABBV) second-quarter earnings and sales beat estimates. Management hikes the EPS guidance on encouraging product sales for immunology drugs.

Wall Street Analysts Believe Genmab (GMAB) Could Rally 52.33%: Here's is How to Trade

by Zacks Equity Research

The consensus price target hints at a 52.3% upside potential for Genmab (GMAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Kinjel Shah headshot

AbbVie (ABBV) Up 24% in a Year: Buy, Sell or Hold the Stock?

by Kinjel Shah

Investors who own AbbVie's (ABBV) stock may stay invested as the company has faced its biggest challenge, Humira's patent cliff- quite well and looks set to return to robust growth next year.

GMAB or TECH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

GMAB vs. TECH: Which Stock Is the Better Value Option?

GMAB vs. TECH: Which Stock Is the Better Value Option?

by Zacks Equity Research

GMAB vs. TECH: Which Stock Is the Better Value Option?

AbbVie (ABBV) Gets CHMP Nod for Lymphoma Drug's Expanded Use

by Zacks Equity Research

AbbVie (ABBV) is seeking approval for Tepkinly in the EU as a monotherapy for the treatment of adult patients with relapsed/refractory follicular lymphoma after two or more prior therapies.

FDA Expands AbbVie's (ABBV) Epkinly Label in Follicular Lymphoma

by Zacks Equity Research

Following the label expansion, AbbVie's (ABBV) Epkinly is the first bispecific antibody approved to treat relapsed/refractory (R/R) follicular lymphoma and R/R diffuse large B-cell lymphoma.

AbbVie (ABBV) Beats on Q1 Earnings & Sales, Ups '24 EPS View

by Zacks Equity Research

AbbVie's (ABBV) first-quarter earnings and sales beat estimates. Management hikes the EPS guidance on the back of encouraging Skyrizi product sales.

Genmab A/S Sponsored ADR (GMAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for Genmab A/S Sponsored ADR (GMAB), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

New Strong Buy Stocks for January 17th

by Zacks Equity Research

SKWD, PHG, BK, PAGS and GMAB have been added to the Zacks Rank #1 (Strong Buy) List on January 17, 2024.

GMAB or TECH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

GMAB vs. TECH: Which Stock Is the Better Value Option?

HRMY or GMAB: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

HRMY vs. GMAB: Which Stock Is the Better Value Option?

AbbVie (ABBV) Lymphoma Drug Gets FDA Breakthrough Therapy Tag

by Zacks Equity Research

The FDA grants breakthrough therapy designation to AbbVie's (ABBV) Epkinly in follicular lymphoma indication. The EMA validates a regulatory filing seeking label expansion for the drug.

Merus N.V. (MRUS) Soars 5.5%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Merus N.V. (MRUS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

AbbVie's (ABBV) Epcoritamab Gets Approval in Europe for DLBCL

by Zacks Equity Research

Tepkinly is AbbVie's (ABBV) second hematological cancer drug to be approved in the European Union. It is also the third blood cancer medicine in AbbVie's portfolio

Seagen's (SGEN) Late-Stage Cervical Cancer Study Meets Goals

by Zacks Equity Research

Seagen (SGEN) and Genmab announce that the late-stage study of Tivdak in the second-line treatment of adult patients with recurrent or metastatic cervical cancer meets the primary and secondary goals.

PBYI vs. GMAB: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

PBYI vs. GMAB: Which Stock Is the Better Value Option?

AbbVie (ABBV) Gets FDA Nod for Lymphoma Drug Epcoritamab

by Zacks Equity Research

The FDA approves AbbVie's (ABBV) epcoritamab, to be marketed as Epkinly, for relapsed/refractory large B-cell lymphoma, a form of NHL. Epkinly is AbbVie's third blood cancer drug.

Strength Seen in Ultragenyx (RARE): Can Its 6.7% Jump Turn into More Strength?

by Zacks Equity Research

Ultragenyx (RARE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks.com featured highlights Genmab, Hologic, ServiceNow and Splunk

by Zacks Equity Research

Genmab, Hologic, ServiceNow and Splunk have been highlighted in this Screen of The Week article.